<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807091</url>
  </required_header>
  <id_info>
    <org_study_id>7910</org_study_id>
    <secondary_id>NCI-2013-00483</secondary_id>
    <secondary_id>7910</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1000945</secondary_id>
    <nct_id>NCT01807091</nct_id>
  </id_info>
  <brief_title>Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome</brief_title>
  <official_title>Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the feasibility of having induction chemotherapy in an&#xD;
      outpatient setting. Patients with acute leukemia (AML) or advanced myelodysplastic syndrome&#xD;
      (MDS), at least 18 years of age will be examined. Treating eligible patients with induction&#xD;
      chemotherapy in an outpatient setting may save in healthcare cost and improve a patients'&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      Assess the feasibility of outpatient induction therapy for acute myeloid leukemia (AML) or&#xD;
      advanced myelodysplastic syndrome (MDS) by examining whether:&#xD;
&#xD;
        1. &gt; 50% of patients treated as outpatients can complete chemotherapy without being&#xD;
           admitted to hospital.&#xD;
&#xD;
        2. &lt; 5% of patients die within 14 days of beginning outpatient chemotherapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive outpatient induction chemotherapy.&#xD;
&#xD;
      STATISTICAL CONSIDERATIONS:&#xD;
&#xD;
      The study was monitored to assure that there was not an excess probability of admission to&#xD;
      the hospital during receipt of outpatient chemotherapy or death within 14 days of initiating&#xD;
      chemotherapy as assessed by Bayesian posterior probabilities using the &quot;predictive&#xD;
      probabilities&quot; tool (MD Anderson Cancer Center Department of Statistics).&#xD;
&#xD;
      Stopping earlier would happen under 2 circumstances:&#xD;
&#xD;
        1. Excess probability that patients required admission to hospital during the 4-7 days of&#xD;
           outpatient chemotherapy (predictive probability be &lt; 0.10, or 7 patients admitted and 3&#xD;
           not admitted among 10 patients enrolled versus the maximum acceptable rate of 4 patients&#xD;
           admitted and 6 not admitted among 10 patients enrolled).&#xD;
&#xD;
        2. Excess probability that patients die during the 14 days after beginning outpatient&#xD;
           treatment (predictive probability be &gt;0.90, for example in cases where there are 2&#xD;
           patient deaths within 14 days and less than 5 patients without deaths within 14 days, or&#xD;
           in any case where there are 3 patient deaths within 14 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2013</start_date>
  <completion_date type="Actual">January 8, 2020</completion_date>
  <primary_completion_date type="Actual">January 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Hospital Admission During Outpatient Induction Chemotherapy</measure>
    <time_frame>During the 4-7 days of outpatient induction chemotherapy</time_frame>
    <description>Feasibility for this study objective would be considered a &quot;success&quot; if &gt;50% of patients treated as outpatients can complete chemotherapy without being admitted to hospital.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death Within 14 Days of Initiating Outpatient Induction Chemotherapy</measure>
    <time_frame>During the 14 days after beginning outpatient induction treatment</time_frame>
    <description>Feasibility for this study objective would be considered a &quot;success&quot; if &lt;5% of patients die within 14 days of beginning outpatient chemotherapy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Adult Acute Myeloid Leukemia</condition>
  <condition>Adult Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Receive outpatient induction chemotherapy</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <other_name>Chemo</other_name>
    <other_name>Chemotherapy (NOS)</other_name>
    <other_name>Chemotherapy, Cancer, General</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
               -  The signed informed consent&#xD;
&#xD;
               -  The benefits/risks of the induction chemotherapy regimen will be reviewed, and a&#xD;
                  second consent may be necessary if the regimen will be administered according to&#xD;
                  a separate protocol&#xD;
&#xD;
          -  AML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS (10-19% blasts in&#xD;
             marrow by morphology or flow cytometry or blood)&#xD;
&#xD;
          -  Treatment-related mortality (TRM) score &lt; 9.21 corresponding to a TRM rate of 3% when&#xD;
             chemotherapy of similar intensity as proposed here is administered to inpatients&#xD;
&#xD;
          -  Blast count =&lt; 10,000&#xD;
&#xD;
          -  Fibrinogen &gt; 200&#xD;
&#xD;
          -  Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal&#xD;
             infection unless determined to be, at the discretion of the investigator, not&#xD;
             clinically significant in the context of this study&#xD;
&#xD;
          -  Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF)&#xD;
             of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing&#xD;
             cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart&#xD;
             failure&#xD;
&#xD;
          -  Patient must have an outpatient caregiver available&#xD;
&#xD;
          -  Patient must live within 30 minutes of the treating physician's office during&#xD;
             outpatient treatment&#xD;
&#xD;
          -  Patient must be willing to return to the treating physician's office for outpatient&#xD;
             follow-up once outpatient treatment is completed&#xD;
&#xD;
          -  Logistical requirements:&#xD;
&#xD;
               -  Space available in infusion room&#xD;
&#xD;
               -  Outpatient infusion pump available if continuous infusion required&#xD;
&#xD;
               -  Case discussed with infusion room nursing staff&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Becker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eli Estey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bozeman Deaconess Hospital</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EvergreenHealth Medical Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skagit Valley Hospital</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympic Medical Center</name>
      <address>
        <city>Port Angeles</city>
        <state>Washington</state>
        <zip>98362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Cooperative</name>
      <address>
        <city>Redmond</city>
        <state>Washington</state>
        <zip>98052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital and Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>December 24, 2020</results_first_submitted>
  <results_first_submitted_qc>February 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Elihu H. Estey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT01807091/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy)</title>
          <description>Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy)</title>
          <description>Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="19" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Related Mortality (TRM) score</title>
          <description>Our institution defines TRM as death within 28 days from initiation of chemotherapy based on the observation that the risk of death declines once 4 weeks has elapsed from treatment start. A calculation is used to predict TRM using patient's age, performance status, if they have secondary AML, albumin, creatinine, platelet count, white blood cell count, and peripheral blood blast percentage. The higher the TRM score, the higher the risk of TRM. Calculator and table of relationship between TRM score and TRM probability found here: https://cstaging.fhcrc-research.org/TRM/Default.aspx</description>
          <units>units on a scale (0-100)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" lower_limit="0.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>AML</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MDS (EB-2)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Newly diagnosed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Relapsed or refractory</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Induction chemotherapy regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Idarubicin, cytarabine, pravastatin (IAP)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cladribine, cytarabine, mitoxantrone, granulocyte colony-stimulating factor (GCLAM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Decitabine, cladribine, cytarabine, mitoxantrone, granulocyte colony-stimulating factor (D-GCLAM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clofarabine, cytarabine, granulocyte colony-stimulating factor (GCLAC)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Decitabine, mitoxantrone, etoposide, cytarabine (D-MEC)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of days of predetermined treatment</title>
          <description>This measure describes the median length (in number of days) the outpatient induction chemotherapy regimen would be administered and was scheduled for. Induction chemotherapy regimen was decided upon by subject, their treating oncologist and clinical care team.</description>
          <units>Days of predetermined treatment</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Year enrolled</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>2010-2013</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2014-2018</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematocrit on day 1</title>
          <units>Percentage of red blood cells in blood</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="23" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet count on day 1</title>
          <units>10 x 10^9 cells/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="12" upper_limit="1108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Hospital Admission During Outpatient Induction Chemotherapy</title>
        <description>Feasibility for this study objective would be considered a &quot;success&quot; if &gt;50% of patients treated as outpatients can complete chemotherapy without being admitted to hospital.</description>
        <time_frame>During the 4-7 days of outpatient induction chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy)</title>
            <description>Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hospital Admission During Outpatient Induction Chemotherapy</title>
          <description>Feasibility for this study objective would be considered a &quot;success&quot; if &gt;50% of patients treated as outpatients can complete chemotherapy without being admitted to hospital.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Admitted during induction chemotherapy period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not admitted during induction chemotherapy period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death Within 14 Days of Initiating Outpatient Induction Chemotherapy</title>
        <description>Feasibility for this study objective would be considered a &quot;success&quot; if &lt;5% of patients die within 14 days of beginning outpatient chemotherapy.</description>
        <time_frame>During the 14 days after beginning outpatient induction treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy)</title>
            <description>Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Death Within 14 Days of Initiating Outpatient Induction Chemotherapy</title>
          <description>Feasibility for this study objective would be considered a &quot;success&quot; if &lt;5% of patients die within 14 days of beginning outpatient chemotherapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of outpatient chemotherapy through day 14 after starting outpatient chemotherapy.</time_frame>
      <desc>Only the following adverse events were recorded:&#xD;
Reasons for hospitalization during planned outpatient administration of chemotherapy&#xD;
Causes of any deaths that occur within 14 days of start of outpatient chemotherapy&#xD;
Other adverse events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy)</title>
          <description>Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Slow accrual was due to initial limitation of enrollment to younger patients receiving initial induction. It was expanded to include older patients, including those receiving salvage induction. The ability to give outpatient induction was often logistically limited. Because of these issues, only 17 patients were treated and it is likely there was significant selection bias, complicating interpretation of the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elihu Estey, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-606-6744</phone>
      <email>eestey@seattlecca.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

